The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...